Pulmonx (LUNG) Cash from Operations Growth (3y) (2022 - 2025)

Pulmonx (LUNG) Cash from Operations Growth (3y) (2022 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.78%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 9.30%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.51%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 22.35%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -48.14%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 50.11%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -14.75%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 0.50%
10 Pulmonx 50.56 Mn -19.19 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 8.42%
Jun 30, 2025 25.94%
Mar 31, 2025 4.17%
Dec 31, 2024 14.26%
Sep 30, 2024 4.63%
Jun 30, 2024 22.99%
Mar 31, 2024 -6.75%
Dec 31, 2023 -5.48%
Sep 30, 2023 -13.92%
Jun 30, 2023 -0.68%
Mar 31, 2023 -8.74%
Dec 31, 2022 -41.37%